Corrigendum

Corrigendum to “HDAC and HMT Inhibitors in Combination with Conventional Therapy: A Novel Treatment Option for Acute Promyelocytic Leukemia”

Aida Vitkevičienė ¹, **Giedrė Skiauterytė**,¹ **Andrius Žučenka**,^{2,3} **Mindaugas Stoškus** ²,
Eglė Gineikienė,² **Veronika Borutinskaitė** ¹, **Laimonas Griškevičius**,^{2,3}
and **Rūta Navakauskienė** ¹

¹Department of Molecular Cell Biology, Institute of Biochemistry, Life Sciences Center, Vilnius University, Sauletekio Av. 7, LT-01257 Vilnius, Lithuania

²Hematology, Oncology, and Transfusion Medicine Centre, Vilnius University Hospital Santaros Klinikos, Santariskiu Str. 2, LT-08661 Vilnius, Lithuania

³Institute of Clinical Medicine, Vilnius University, M. K. Ciurlionio Str. 21, LT-03101 Vilnius, Lithuania

Correspondence should be addressed to Aida Vitkevičienė; aida.vitkeviciene@gmc.vu.lt

Received 7 August 2020; Accepted 7 August 2020; Published 4 September 2020

Copyright © 2020 Aida Vitkevičienė et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

In the article titled “HDAC and HMT Inhibitors in Combination with Conventional Therapy: A Novel Treatment Option for Acute Promyelocytic Leukemia” [1], the last author was mistakenly linked to the second affiliation instead of the first. The corrected author list and affiliations are shown above.

References

- [1] A. Vitkevičienė, G. Skiauterytė, A. Žučenka et al., “HDAC and HMT inhibitors in combination with conventional therapy: a Novel treatment option for acute promyelocytic leukemia,” *Journal of Oncology*, vol. 2019, Article ID 6179573, 11 pages, 2019.